Sign In to Follow Application
View All Documents & Correspondence

Compositions For Lightening Skin Color.

Abstract: Skin lightening additives and skin lightening compositions having at least one of a heterosubstituted, saturated or unsaturated aliphatic acid are described. The compositions are suitable for topical application and may comprise 12-hydroxystearic acid, ricinoleic acid or both.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
09 December 2010
Publication Number
11/2011
Publication Type
INA
Invention Field
CHEMICAL
Status
Email
info@krishnaandsaurastri.com
Parent Application
Patent Number
Legal Status
Grant Date
2017-11-20
Renewal Date

Applicants

HINDUSTAN UNILEVER LIMITED
HINDUSTAN LEVER HOUSE, 165/166 BACKBAY RECLAMATION, MUMBAI,400020, INDIA

Inventors

1. MADISON STEPHEN ALEN
CONOPCO INC., D/B/A UNILEVER, 40 MERRITT BOULEVARD, TRUMBULL, CONNECTICUT 06611, UNITED STATE OF AMERICA

Specification

FORM - 2
THE PATENTS ACT, 1970
(39 of 1970)
&
The Patents Rules, 2003
COMPLETE SPECIFICATION
(See Section 10 and Rule 13)
COMPOSITIONS FOR LIGHTNINIG SKIN COLOR
HINDUSTAN UNILEVER LIMITED, a company incorporated under
the Indian Companies Act, 1913 and having its registered office
at 165/166, Backbay Reclamation, Mumbai -400 020, Maharashtra, India
The following specification particularly describes the invention and the manner in which it is to be performed

COMPOSITIONS FOR LIGHTENING SKIN COLOR
5
FIELD OF THE INVENTION
The present invention is directed to a skin lightening additive as well as compositions comprising the same. More particularly the present invention is directed to a cosmetic composition comprising a skin lightening additive whereby the skin lightening additive 10 comprises a heterosubstituted, saturated or unsaturated aliphatic acid, or a mixture thereof. The skin lightening additive, when used, results in a cosmetic composition that can provide moisturizing benefits. Moreover it has been unexpectedly discovered that such aliphatic acids have skin lightening benefits when topically applied.
15 BACKGROUND OF THE INVENTION
Many consumers are concerned with the characteristics of their skin. For example consumers are concerned with the degree of pigmentation of their skin, freckles and/or age spots. Other consumers wish to reduce skin darkening caused by exposure to sunlight. To meet the needs of consumers, many attempts have been made to
20 develop products that improve skin characteristics. The products developed thus far often tend to have low efficacy, undesirable side effects or both. Furthermore such products can be expensive and are often not an alternative for lower income consumers.
25 There is an increasing interest to develop a cosmetic composition that comprises new skin lightening additives. This invention is directed to cosmetic compositions that comprise new skin lightening additives. The cosmetic compositions of the present invention preferably comprise, as a lightening additive, compounds like 12-hydroxystearic acid, ricinoleic acid or both. The cosmetic compositions of this
30 invention result in a decrease in melanin content which is at least 8% lower {preferably at least about 11% lower) when comparing MelanoDerm™ cultures treated with the same to MelanoDerm cultures that have not been subjected to a composition with the newly discovered skin lightening additives of this invention.

ADDITIONAL INFORMATION
Efforts have been disclosed for making skin care cosmetic compositions. In US 6 875 425, skin lightening agents with 4-substituted resorcinol derivative compounds are described. 5
Other efforts have been disclosed for making skin treatment compositions. In US 7 250 158 and US 7 247 294, methods for treating with skin lightening agents are described.
10 Still other efforts have been disclosed for treating skin. In US 5 998 423, compositions with polycyclic nitrogen heterocycles are described.
None of the additional information above describes skin lightening compositions that comprise, as a lightening additive, a heterosubstituted, saturated or unsaturated 15 aliphatic acid, or mixture thereof.
SUMMARY OF THE INVENTION
In a first aspect, the present invention is directed to a skin lightening additive, the skin lightening additive comprising a heterosubstituted, saturated or unsaturated aliphatic 20 acid, or both.
In a second aspect, the present invention is directed to a cosmetic composition for skin lightening, the cosmetic composition comprising a skin lightening agent comprising the skin lightening additive of the first aspect of this invention. 25
In a third aspect, the present invention is directed to a method for lightening skin with the cosmetic composition of the second aspect of this invention.
All other aspects of the present invention will more readily become apparent upon 30 considering the detailed description and examples which follow.
As used herein, a decrease in melanin content means a melanin content decrease when comparing two (2), three week old MatTek MelanoDerm cultures that have not

been treated with a composition comprising the skin lightening additive of this invention to two (2), three week old MatTek MelanoDerm cultures that have been treated with a composition comprising the skin lightening additive of this invention wherein treated means: 5
(a) placing the MelanoDerm culture within a six (6) well tissue culture dish and set about 0.3 cm off of the tissue culture dish;
(b) subjecting the MelanoDerm culture to 0.1 and 5 micromolar compositions having the skin lightening additive of this invention, the composition being one
10 prepared from a 10 millimolar solution of skin lightening additive and carrier
(e.g. dimethyl sulfoxide) having been diluted with Dulbecco's Modified Eagle Media; and
(c) comparing the treated and untreated cultures by obtaining average melanin
content (expressed in micrograms) by extracting melanin from MelanoDerm and
15 obtaining absorbance readings at 490 nm (OD490) using a commercially available
spectrophotometer like a Hach spectrophotometer.
Cosmetic composition, as used herein, is meant to include a composition for topical application to skin of mammals, especially humans. Such a composition may be
20 generally classified as leave-on or rinse off, and is meant to include conditioners or tonics, lipsticks, color cosmetics, and general topical compositions that in some fashion and at the very least reduces the effect of melanin on keratinocytes. Lightening and whitening as used herein are meant to mean the same and they include the lightening of skin directly as well as the lightening of spots on the skin, like age spots and
25 freckles, Dulbecco's Modified Eagle Media means the nutrient solution sold by MatTek Corporation and treated and used according to instructions supplied with the product commercially identified as MEL30010BBLLMM. Skin lightening additive means a component suitable to result in physical, but especially biological whitening (i.e. a reduction in melanin production) whereby the skin lightening additive can comprise,
30 consist essentially of or consist of the skin lightening additive. MelanoDerm means the product having normal, human-derived epidermal keratinocytes and melanocytes which have been cultured to form a multilayered, highly differentiated model of the human epidermis, all of which is made commercially available by MatTek Corporation.

Unsaturated, as used herein, means having at least one bond that is not sp3 hybridized. Comprising, as used herein, is meant to include consisting essentially of and consisting of.
5 The cosmetic composition of the present invention can be in the form of a liquid, lotion, cream, serum, gel, soap bar or toner, or applied via a face mask or patch. The composition of this invention is one that at the very least, lightens skin when skin is meant to include skin on the face, neck, chest, back, arms, hands, legs and scalp. All ranges identified herein are meant to implicitly include all ranges subsumed therein, if, 10 for example, reference to the sarne is not explicitly made.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The only [imitation with respect to the skin lightening additive that may be used in this invention is that the same may be used in a topical composition suitable for use on 15 humans. The preferred additive is a heterosubstituted, saturated or unsaturated aliphatic acid or a mixture thereof.
In a most preferred embodiment, the skin lightening additive employed in the present invention comprises a compound having the formulae:

or a mixture thereof,
25 wherein each R is independently hydrogen, hydroxyl, C1-6 aikoxy, C1-6 alkyl, arylalkyi or an amine, with the proviso that at least one R group comprises a heteroatom; each R1

is independently hydrogen, C1-6 alkoxy, C1-6 alkyl, aryiaikyi or an amine; n is an integer from 7 to 19; and s and e are each independently an integer from 0 to 8, where s+e ≥ 6 ; q is an integer from 6 to 11; each r is independently an integer from 0 to 1, with the proviso that each r is not 1 when x is 1; x is an integer from 0 to 1 with the proviso 5 that x is 0 when at least one r is 1; and each t is independently an integer from 1 to 7.
The preferred compounds suitable for use in this invention {either alone or in a mixture) are aleurittc acid; phloionolic acid; 9, 10, 13-trihydroxy-ll-octadecenoic acid; 9, 1 3-dihydroxy-12-ethoxy-10-octadecenoic acid; 9-hydroxy-10,12-octadecadienoic
10 acid; 4, 14-dihydroxy-octadecanoic acid; 12-hydroxystearic acid (12-hydroxyoctadecanoic acid); lesquerolic acid; ricinelaidic acid; ambrettolic acid, and rincinoleic acid {12-hydroxy-9-cis-octadecanoic acid) as represented by either formula I or II. Other preferred compounds suitable for use in this invention include beta-dimorphecolic acid; densipolic acid; 8-methoxy-13-hydroxy-9, 11-octadecadienoic acid;
15 7-oxo-octadecanoic acid; 9-oxo-octadecanoic acid; 12-oxo-octadecanoic acid and 10-oxo-14-methyl-pentadecanoic acid as represented by formula III. Furthermore it is within the scope of the present invention to include any derivative (like an ester derivative) and/or salt of the acid represented by formulae l-III, and especially, Mg, Na and/or Ca salts thereof. Such compounds are commercially available from suppliers 20 like Vertellus Specialties Inc. Welch, Home & Clark Co. Inc. as well as Croda Chemicals.
The cosmetic compositions of the present invention typically comprise from 0.001 to 15% by weight, and preferably from 0.1 to 12%, and most preferably from 1 to 10% by weight skin lightening additive based on total weight of the cosmetic composition 25 and including all ranges subsumed therein.
While it is within the scope of this invention for the skin lightening additive to consist essentially of and to consist of heterosubstituted, saturated or unsaturated aliphatic acid or a mixture thereof, in an often desired embodiment, the skin lightening additive 30 of this invention comprises from 0.2 to 95%, and preferably from 10 to 85%, and most preferably from 30 to 65% by weight heterosubstituted saturated or unsaturated aliphatic acid or a mixture thereof based on total weight of skin lightening additive and including all ranges subsumed therein.

(n yet another desired embodiment, the cosmetic composition of this invention comprises from 2 to 9%, and preferably from 3 to 8%, and most preferably from 3 to 6% by weight heterosubstituted, saturated or unsaturated aliphatic acid, or a mixture thereof based on total weight of the cosmetic composition and including all ranges 5 subsumed therein,
When used in combination the weight ratio of heterosubstituted, saturated or unsaturated aliphatic acid to heterosubstituted, saturated aliphatic acid is from 5:95 to 95:5, and preferably from 20:80 to 80:20, and most preferably from 40:60 to 60:40 10 including all ratios subsumed therein.
It should be known that commercially acceptable and conventional vehicles may be used acting as diluents, dispersants and/or carriers for the skin lightening agents and additives described herein and for any other optional but often preferred additives.
15 Therefore the cosmetically acceptable vehicle suitable for use in this invention may be aqueous-based, anhydrous or an emulsion whereby a water-in-oil or oil-in-water emufsion is generally preferred. If the use of water is desired, water typically makes up the balance of the cosmetic composition, and preferably makes up from 5 to 99%, and most preferably from 40 to 80% by weight of the cosmetic composition including all
20 ranges subsumed therein.
In addition to water, organic solvents may be optionally included to act as carriers or to assist carriers within the compositions of the present invention. Illustrative and non-limiting examples of the types of organic solvents suitable for use in the present 25 invention include alkanols like ethyl and isopropyl alcohol, mixtures thereof or the like.
Other optional additives suitable for use include ester oils like isopropyl myristate, cetyl myristate, 2-octyidodecyl myristate, avocado oil, almond oil, olive oil, neopentylglycol dicaprate, mixtures thereof or the like. Typically such ester oils assist in emulsifying 30 the cosmetic composition of this invention, and an effective amount is often used to yield a stable, and most preferably water-in-oil emulsion.

Emollients may also be used, if desired, as carriers within the cosmetic composition of the present invention. Alcohols like 1-hexadecanol (i.e. cetyl alcohol) and phenoxyethanol are often desired as are the emollients generally classified as silicone oils and synthetic esters. Silicone oils suitable for use include cyclic or linear 5 polydimethylsiloxanes containing from 3 to 9, preferably from 4 to 5, silicon atoms. Non-volatile silicone oils useful as an emollient material in the inventive cosmetic composition described herein include polyalkyi siloxanes, polyalkylaryl siloxanes and polyether siloxane copolymers. The essentially non-volatile polyalkyi siloxanes useful herein include, for example, polydimethylsiloxanes. • 10
The ester emollients that may optionally be used are:
(1) Alkenyl or alkyl esters of fatty acids having 10 to 20 carbon atoms. Examples thereof include isoarachidyl neopentanoate, isononyl isonanonoate, oleyl myristate, oley stearate and oleyl o/eate.
15 (2) Ether-esters such as fatty acid esters of ethoxylated fatty alcohols.
(3) Polyhydric alcohol esters. Ethylene glycol mono- and di-fatty acid esters, diethylene glycol mono-and di-fatty acid esters, polyethylene glycol (200-6000) mono- and di-fatty acid esters, propylene glycol mono- and di-fatty acid esters, polypropylene glycol 2000 monooleate, polypropylene glycol 2000 monostearate,
20 ethoxylated propylene glycol monostearate, glyceryl mono- and di-fatty acid
esters, polyglycerol poly-fatty esters, ethoxylated glyceryl mono-stearate, 1,3-butylene glycol monostearate, 1,3-butylene glycol distearate, polyoxyethylene polyol fatty acid ester, sorbitan fatty acid esters, and polyoxyethylene sorbitan fatty acid esters are satisfactory polyhydric alcohol esters.
25 (4) Wax esters such as beeswax, spermaceti, stearyl stearate and arachidyl behenate. (5) Sterols esters, of which cholesterol fatty acid esters are examples.
Emollients when used, typically make up from 0.1 to 50% by weight of the cosmetic composition including all ranges subsumed therein. 30
Fatty acids having from 10 to 30 carbon atoms may also be included as cosmetically acceptable carriers within the composition of the present invention. Illustrative examples of such fatty acids include pelargonic, lauric, myristic, palmitic, stearic,

isostearic, oleic, iinoleic, arachidic, behenic or erucic acid and mixtures thereof. Compounds that are believed to enhance skin penetration, like dimethyl sulfoxide, may also be used as an optional carrier.
5 Humectants of the polyhydric alcohol type may also be employed in the cosmetic compositions of this invention. The humectant often aids in increasing the effectiveness of the emollient, reduces scaling, stimulates removal of built-up scale and improves skin feel. Typical polyhydric alcohols include glycerol, polyalkyiene glycols and more preferably alkylene polyols and their derivatives, including propylene glycol,
10 dipropylene glycol, polypropylene glycol, polyethylene glycol and derivatives thereof, sorbitol, hydroxypropyi sorbitol, hexylene glycol, 1,3-butylene glycol, 1,2,6-hexanetriol, ethoxylated glycerol, propoxylated glycerol and mixtures thereof. For best results the humectant is preferab(y propylene gfycof or sodium hyafuronate. The amount of humectant may range anywhere from 0.2 to 25%, and preferably from 0.5 to 15% by
15 weight of the cosmetic composition based on total weight of the cosmetic composition and including all ranges subsumed therein.
Thickeners may also be utilized as part of the cosmetically acceptable carrier in the cosmetic compositions of the present invention. Typical thickeners include cross-linked
20 acrylates (e.g. Carbopol 982), hydrophobically-modified acrylates (e.g. Carbopol 1382), cellulosic derivatives and natural gums. Among useful cellulosic derivatives are sodium carboxymethylcellulose, hydroxypropyi methycellulose, hydroxypropyi cellulose, hydroxyethyl cellulose, ethyl cellulose and hydroxymethyl cellulose. Natural gums suitable for the present invention include guar, xanthan, sclerotium, carrageenan,
25 pectin and combinations of these gums. Amounts of the thickener may range from 0.0 to 5%, usually from 0.001 to 1%, optimally from 0.01 to 0.5% by weight.
Collectively, the water, solvents, silicones, esters, fatty acids, humectants and/or thickeners will constitute the cosmetically acceptable carrier in amounts from 1 to 30 99.9%, preferably from 80 to 99% by weight.
Surfactants may also be present in cosmetic compositions of the present invention. Total concentration of the surfactant will range from 0 to 40%, and preferably from 0 to 20%,

optimaify from 0 to 5% by weight of the composition. The surfactant may be selected from the group consisting of anionic, nonionic, cationic and amphoteric actives. Particularly preferred nonionic surfactants are those with a C10-C20 fatty alcohol or acid hydrophobe condensed with from 2 to 100 moles of ethylene oxide or propylene oxide 5 per mole of hydrophobe; C2-C10 alkyl phenols condensed with from 2 to 20 moles of alkylene oxide; mono- and di- fatty acid esters of ethylene glycol; fatty acid monoglyceride; sorbitan, mono- and di- C8-C20 fatty acids; block copolymers (ethylene oxide/propylene oxide); and polyoxyethyjene sorbitan as well as combinations thereof. Alkyl polyg lycos ides and saccharide fatty amides (e.g. methyl gluconamides) are also 10 suitable nonionic surfactants.
Preferred anionic surfactants include soap, alkyl ether sulfate and sulfonates, alkyl sulfates and sulfonates, alkylbenzene sulfonates, atkyl and dialkyi sulfosuccinates, C8-C20 acyl isothionates, acyl glutamates, C8-C10 alkyl ether phosphates and combinations thereof.
15
Perfumes may be used in the cosmetic composition of this invention. Illustrative non-limiting examples of the types of perfumes that may be used include those comprising terpenes and terpene derivatives like those described in Bauer, K., et al.. Common Fragrance and Flavor Materials. VCH Publishers (1990).
20
Illustrative yet non-limiting examples of the types of fragrances that may be used in this invention include myrcene, dihydromyrenol, citral, tagetone, cis-geranic acid, citronellic acid, or cis-geranic acid nitriie, mixtures thereof or the like.
25 Preferably, the amount of fragrance employed in the cosmetic composition of this invention is.in the range from 0.0% to 10%, more preferably 0.00001% to 5 wt %, most preferably 0.0001% to 2%.
Various types of optional additional active ingredients may be used in the cosmetic
30 compositions of the present invention. Actives are defined as skin benefit agents
other than emollients and other than ingredients that merely improve the physical
characteristics of the composition. Although not limited to this category, general

examples include talcs and silicas, as well as a!pha-hydroxy acids, beta-hydroxy acids, peroxides, zinc salts and sunscreens.
Beta-hydroxy acids include salicylic acid, for example. Zinc pyrithione is an example of 5 the zinc salts useful in the cosmetic composition of the present invention.
Sunscreens include those materials commonly employed to block ultraviolet light. Illustrative compounds are the derivatives of PABA, cinnamate and salicylate. For example avobenzophenone (Parsol 1789®), octyl methoxycinnamate and 2-hydroxy-4-
10 methoxyl benzophenone (also known as oxybenzone) can be used. Octyl methoxycinnamate and 2-hydroxy-4-methoxy benzophenone are commercially available under the trademarks Parsol MCX and Benzophenone-e respectively. The exact amount of sunscreen employed in the compositions can vary depending upon the degree of protection desired from the sun's UV radiation. Additives that reflect or
15 scatter the suns rays may also be employed. These additives include oxides like zinc oxide and titanium dioxide.
Many cosmetic compositions, especially those containing water, should be protected against the growth of potentially harmful microorganisms. Anti-microbial
20 compounds, such as triclosan, and preservatives are typically necessary. Suitable preservatives include alkyl esters of p-hydroxybenzoic acid, hydantoin derivatives, propionate salts and a variety of quaternary ammonium compounds. Particularly preferred preservatives of this invention are methyl paraben, propyl paraben, phenoxyethanol and benzyl alcohol. Preservatives will usually be employed in
25 amounts ranging from 0.1% to 2% by weight of the composition.
Still other optional ingredients that may be used with the cosmetic composition of this invention include dioic acids (e.g. malonic acid and sebacic acid), antioxidants like vitamin E, vitamins like niacinamide and vitamin C and its derivatives, recorcinols and 30 its derivatives (including those esterified with, for example, ferulic acid, vanillic acid or the like) and retinoids, including retinoic acid, retinal, retinol and retinyl esters, conjugated linoleic acid, petroselinic acid and mixtures thereof, as well as any other

conventional ingredients well known for wrinkle-reducing, skin whitening, anti-acne effects and reducing the impact of sebum.
The cosmetic compositions of the present invention are intended for use primarily as a 5 product for topical application to human skin, especially and at least as a product for lightening the skin. Thus the inventor has discovered that the described aliphatic acids have excellent skin lightening capabilities whereby the same may be employed as skin lightening additives in topical cosmetic compositions that are applied topically to areas of the skin where lightening or whitening is desired. Other benefits may include skin
10 moisturizing, decreasing the effect of sebum on the skin and skin wrinkle reducing, Often the cosmetic composition of the present invention has a melting point from 30°C to 45°C, including all ranges subsumed therein. In an especially preferred embodiment, the cosmetic composition of the present invention has a pH from 4.5 to 7.5 including all ranges subsumed therein.
15
When making the cosmetic composition of the present invention, the desired ingredients are mixed in no particular order and usually at temperatures from.70 to SO°C and under atmospheric pressure.
20 The packaging for the composition of this invention can be a patch, bottle, tube, roll-ball applicator, propellant driven aerosol device, squeeze container or lidded jar.
The examples which follow are provided to illustrate and facilitate an understanding of the invention. The examples are not intended to limit the scope of the claims.
25
Examples
Commercially available human skin equivalents (MelanoDerm™ from MatTek) were obtained for testing the impact of heterosubstituted, saturated or unsaturated aliphatic acid on melanogenesis. Solutions having a final concentration of 0.1 to 5
30 micromolar were prepared from a 10 millimolar dimethyl sulfoxide stock solution and dosed ten (10) times in a three (3) week period into the media of the MelanoDerm cultures. The media consisted of commercially available basal Dulbecco's Modified Eagles media prepared and treated in the manner set forth in the manufacturer's

instructions. For long term maintenance of the MelanoDerms, the basal media was supplemented with basic fibroblast growth factor (bFGF) and alpha melanocyte stimulating hormone (MSH) to stimulate melanocyte growth and melanogenesis. Each treatment condition was done in duplicate and three (3) sets were made for each 5 treatment as well as for a control (culture not treated with the aliphatic acid). The cultures were maintained at a temperature of 37°C and incubated in a humidified, 5% CO2 incubator during the dosing period, but removed while being dosed.
After a three (3) week period, the melanoDerm cultures were removed and solubilized 10 in a centrifuge tube containing 250 microliters of Solvable reagent {GNE9100, Packard) for sixteen (16) hours (overnight) in a 60°C oven. Following solubilization, the centrifuge tube containing the sample was spun at 12,000 g for five (5) minutes. Two hundred (200) microliters of supernatant were removed and placed in a ninety-six (96) well plate. A spectrophotometer was used to measure the absorbance of the 15 supernatant at 490 nm. A standard curve using synthetic melanin was set up in parallel to allow quantitation of melanin, in micrograms, of the samples. The results are provided below:
Tables
20 Active MC* Value Range Average MC AMC
Control 75.0-78.4 77.2
Aliphatic acid' 67.9-69.2 68,6 8.6
25
Active MC Value Range Average MC AMC
Control 76.0-78.4 77.2
30 Aliphatic acid" 69.9-67.6 68,8 8.4
i = ricinoleic acid (0,1uM) 35 ii = 12-hydroxystearic acid (5uM) * MC = melanin content

The results, as they relate to MelanoDerm cultures, show that cosmetic compositions with the aliphatic acids of this invention unexpectedly result in skin lightening.

CLAIMS
1. A cosmetic composition comprising:
a. a skin lightening additive which is 12-hydroxystearic acid and/or a salt thereof
b. a cosmetic carrier; and
c. niacinamide.
2. A cosmetic composition according to claim 1 wherein the composition further comprises a
dioic acid.
3. A cosmetic composition according to claim 1 or claim 2 wherein the cosmetic composition
further comprises an alpha-hydroxy, beta-hydroxy acid, sunscreen or a mixture thereof.
4. A cosmetic composition according to anyone of the preceding claims wherein the
composition iurdier comprises conjugated linoleic acid, petroselinic acid or both.
5. A cosmetic composition according to anyone of the preceding claims wherein the composition further comprises antioxidant
6. A cosmetic composition according to anyone of the preceding claims additionally comprising a skin lightening additive which is an unsaturated aliphatic acid selected from the group consisting of lesquerolic acid; ricinelaidic acid; ambrettolic acid; ricinoleic acid; beta-dimorphecolic acid; densipoiic acid; 8-methoxy-13-hydroxy-9,11-octadecadienoic acid; 7-oxo-octadecanoic acid; 9-oxo-octadecanoic acid; H-oxo-octadecanoic acid; 10-oxo-14-methyl-pentadecanoic acid; and a mixture thereof.
7. A cosmetic composition according to claim 6 wherein the unsaturated aliphatic acid is 12-oxo-octadecanoic acid.
8. A cosmetic composition according to claim 6 or claim 7 wherein the weight ratio of 12-hydroxystearic acid and/or a salt thereof and the unsaturated aliphatic acid is from 5:95 to 95:5, preferably 10:90 to 90:10, most preferably 40:60 to 60:40.
9. A cosmetic composition according to anyone of the preceding claims wherein the 12-hydroxystearic acid and/or a salt thereof and the unsaturated aliphatic acid comprises 2-9, preferably 3-8, most preferably 3-6% by weight of the composition.
10. A cosmetic composition according to anyone of claims 1 to 8 wherein the amount of skin lightenmg additive is 0.001-15, preferably 0.1-12, most preferably 1-10% by weight of the composition.
11. A cosmetic composition according to claim 10 wherein the skin lightening additive comprises from 0.2 to 95%, preferably from 10 to 85% and most preferably from 30 to 65% by weight 12-hydroxystearic acid and/or a salt thereof, and/or the unsaturated aliphatic acid based on total weight of the skin lightening additive.

12. A cosmetic composition according to anyone of the preceding claims wherein the composition additionally comprises a skin lightening additive which is an ester of 12-hydroxysteario acid.
13. A cosmetic composition according to claim 2 wherein the dioic acid is maJonic acid or sebacic acid.
14. A method for lightening skin color comprising the step of contacting skin with a composition according to anyone of the preceding claims,

Documents

Orders

Section Controller Decision Date

Application Documents

# Name Date
1 2646-MUMNP-2010-FORM 3(10-12-2013).pdf 2013-12-10
1 2646-MUMNP-2010-FORM-27 [27-09-2024(online)].pdf 2024-09-27
2 2646-MUMNP-2010-FORM 3(10-11-2014).pdf 2014-11-10
2 2646-MUMNP-2010-RELEVANT DOCUMENTS [29-09-2023(online)].pdf 2023-09-29
3 2646-MUMNP-2010-RELEVANT DOCUMENTS [14-09-2022(online)].pdf 2022-09-14
3 2646-MUMNP-2010-FORM-3-(25-04-2015).pdf 2015-04-25
4 Other Document [13-07-2016(online)].pdf 2016-07-13
4 2646-MUMNP-2010-RELEVANT DOCUMENTS [09-09-2021(online)].pdf 2021-09-09
5 Examination Report Reply Recieved [13-07-2016(online)].pdf 2016-07-13
5 2646-mumnp-2010-claims.doc 2018-08-10
6 Description(Complete) [13-07-2016(online)].pdf 2016-07-13
6 2646-mumnp-2010-claims.pdf 2018-08-10
7 2646-MUMNP-2010-POWER OF ATTORNEY-(20-07-2016).pdf 2016-07-20
7 2646-MUMNP-2010-CORRESPONDENCE(11-1-2011).pdf 2018-08-10
8 2646-MUMNP-2010-CORRESPONDENCE-(20-07-2016).pdf 2016-07-20
8 2646-MUMNP-2010-CORRESPONDENCE(2-3-2012).pdf 2018-08-10
9 2646-MUMNP-2010-AFFIDAVIT-(20-07-2016).pdf 2016-07-20
9 2646-MUMNP-2010-CORRESPONDENCE(3-4-2013).pdf 2018-08-10
10 2646-MUMNP-2010-Correspondence-060815.pdf 2018-08-10
10 Other Document [09-06-2017(online)].pdf 2017-06-09
11 2646-mumnp-2010-correspondence.pdf 2018-08-10
11 Form 26 [09-06-2017(online)].pdf 2017-06-09
12 2646-mumnp-2010-description(complete).pdf 2018-08-10
12 Form 13 [09-06-2017(online)].pdf 2017-06-09
13 2646-mumnp-2010-form 1.pdf 2018-08-10
13 2646-MUMNP-2010-ORIGINAL UNDER RULE 6 (1A)-19-06-2017.pdf 2017-06-19
14 2646-MUMNP-2010-FORM 13(10-2-2012).pdf 2018-08-10
14 2646-MUMNP-2010-FORM 3-18-07-2017.pdf 2017-07-18
15 2646-MUMNP-2010-FORM 18(2-3-2012).pdf 2018-08-10
15 2646-MUMNP-2010-Response to office action (Mandatory) [06-10-2017(online)].pdf 2017-10-06
16 2646-mumnp-2010-form 2(title page).pdf 2018-08-10
16 2646-MUMNP-2010-FORM-26 [31-10-2017(online)].pdf 2017-10-31
17 2646-MUMNP-2010-Correspondence to notify the Controller (Mandatory) [03-11-2017(online)].pdf 2017-11-03
18 2646-mumnp-2010-Written submissions and relevant documents (MANDATORY) [17-11-2017(online)].pdf 2017-11-17
18 2646-mumnp-2010-form 2.pdf 2018-08-10
19 2646-MUMNP-2010-FORM 3(12-8-2011).pdf 2018-08-10
19 2646-MUMNP-2010-PatentCertificate20-11-2017.pdf 2017-11-20
20 2646-MUMNP-2010-FORM 3(15-2-2011).pdf 2018-08-10
20 2646-MUMNP-2010-IntimationOfGrant20-11-2017.pdf 2017-11-20
21 2646-MUMNP-2010-FORM 3(15-2-2012).pdf 2018-08-10
21 2646-MUMNP-2010_EXAMREPORT.pdf 2018-08-10
22 2646-MUMNP-2010-FORM 3(22-6-2013).pdf 2018-08-10
22 2646-mumnp-2010-wo international publication report a1.pdf 2018-08-10
23 2646-MUMNP-2010-FORM 3(23-1-2013).pdf 2018-08-10
23 2646-MUMNP-2010-OTHERS-060815.pdf 2018-08-10
24 2646-MUMNP-2010-FORM 3(26-5-2014).pdf 2018-08-10
24 2646-mumnp-2010-other document.pdf 2018-08-10
25 2646-MUMNP-2010-FORM 3(8-8-2012).pdf 2018-08-10
25 2646-MUMNP-2010-Original Under Rule 6(1 A)Form 3-270117.pdf 2018-08-10
26 2646-MUMNP-2010-Form 3-091015.pdf 2018-08-10
26 2646-mumnp-2010-HearingNoticeLetter.pdf 2018-08-10
27 2646-MUMNP-2010-Form 3-160816.pdf 2018-08-10
27 2646-MUMNP-2010-GENERAL POWER OF ATTORNEY(11-1-2011).pdf 2018-08-10
28 2646-MUMNP-2010-Form 3-190316.pdf 2018-08-10
28 2646-mumnp-2010-form pct-isa-210.pdf 2018-08-10
29 2646-mumnp-2010-form 3.pdf 2018-08-10
29 2646-mumnp-2010-form 5.pdf 2018-08-10
30 2646-mumnp-2010-form 3.pdf 2018-08-10
30 2646-mumnp-2010-form 5.pdf 2018-08-10
31 2646-MUMNP-2010-Form 3-190316.pdf 2018-08-10
31 2646-mumnp-2010-form pct-isa-210.pdf 2018-08-10
32 2646-MUMNP-2010-Form 3-160816.pdf 2018-08-10
32 2646-MUMNP-2010-GENERAL POWER OF ATTORNEY(11-1-2011).pdf 2018-08-10
33 2646-MUMNP-2010-Form 3-091015.pdf 2018-08-10
33 2646-mumnp-2010-HearingNoticeLetter.pdf 2018-08-10
34 2646-MUMNP-2010-FORM 3(8-8-2012).pdf 2018-08-10
34 2646-MUMNP-2010-Original Under Rule 6(1 A)Form 3-270117.pdf 2018-08-10
35 2646-mumnp-2010-other document.pdf 2018-08-10
35 2646-MUMNP-2010-FORM 3(26-5-2014).pdf 2018-08-10
36 2646-MUMNP-2010-FORM 3(23-1-2013).pdf 2018-08-10
36 2646-MUMNP-2010-OTHERS-060815.pdf 2018-08-10
37 2646-MUMNP-2010-FORM 3(22-6-2013).pdf 2018-08-10
37 2646-mumnp-2010-wo international publication report a1.pdf 2018-08-10
38 2646-MUMNP-2010-FORM 3(15-2-2012).pdf 2018-08-10
38 2646-MUMNP-2010_EXAMREPORT.pdf 2018-08-10
39 2646-MUMNP-2010-FORM 3(15-2-2011).pdf 2018-08-10
39 2646-MUMNP-2010-IntimationOfGrant20-11-2017.pdf 2017-11-20
40 2646-MUMNP-2010-FORM 3(12-8-2011).pdf 2018-08-10
40 2646-MUMNP-2010-PatentCertificate20-11-2017.pdf 2017-11-20
41 2646-mumnp-2010-form 2.pdf 2018-08-10
41 2646-mumnp-2010-Written submissions and relevant documents (MANDATORY) [17-11-2017(online)].pdf 2017-11-17
42 2646-MUMNP-2010-Correspondence to notify the Controller (Mandatory) [03-11-2017(online)].pdf 2017-11-03
43 2646-mumnp-2010-form 2(title page).pdf 2018-08-10
43 2646-MUMNP-2010-FORM-26 [31-10-2017(online)].pdf 2017-10-31
44 2646-MUMNP-2010-FORM 18(2-3-2012).pdf 2018-08-10
44 2646-MUMNP-2010-Response to office action (Mandatory) [06-10-2017(online)].pdf 2017-10-06
45 2646-MUMNP-2010-FORM 3-18-07-2017.pdf 2017-07-18
45 2646-MUMNP-2010-FORM 13(10-2-2012).pdf 2018-08-10
46 2646-mumnp-2010-form 1.pdf 2018-08-10
46 2646-MUMNP-2010-ORIGINAL UNDER RULE 6 (1A)-19-06-2017.pdf 2017-06-19
47 2646-mumnp-2010-description(complete).pdf 2018-08-10
47 Form 13 [09-06-2017(online)].pdf 2017-06-09
48 2646-mumnp-2010-correspondence.pdf 2018-08-10
48 Form 26 [09-06-2017(online)].pdf 2017-06-09
49 2646-MUMNP-2010-Correspondence-060815.pdf 2018-08-10
49 Other Document [09-06-2017(online)].pdf 2017-06-09
50 2646-MUMNP-2010-AFFIDAVIT-(20-07-2016).pdf 2016-07-20
50 2646-MUMNP-2010-CORRESPONDENCE(3-4-2013).pdf 2018-08-10
51 2646-MUMNP-2010-CORRESPONDENCE(2-3-2012).pdf 2018-08-10
51 2646-MUMNP-2010-CORRESPONDENCE-(20-07-2016).pdf 2016-07-20
52 2646-MUMNP-2010-CORRESPONDENCE(11-1-2011).pdf 2018-08-10
52 2646-MUMNP-2010-POWER OF ATTORNEY-(20-07-2016).pdf 2016-07-20
53 2646-mumnp-2010-claims.pdf 2018-08-10
53 Description(Complete) [13-07-2016(online)].pdf 2016-07-13
54 Examination Report Reply Recieved [13-07-2016(online)].pdf 2016-07-13
55 Other Document [13-07-2016(online)].pdf 2016-07-13
55 2646-MUMNP-2010-RELEVANT DOCUMENTS [09-09-2021(online)].pdf 2021-09-09
56 2646-MUMNP-2010-RELEVANT DOCUMENTS [14-09-2022(online)].pdf 2022-09-14
56 2646-MUMNP-2010-FORM-3-(25-04-2015).pdf 2015-04-25
57 2646-MUMNP-2010-RELEVANT DOCUMENTS [29-09-2023(online)].pdf 2023-09-29
57 2646-MUMNP-2010-FORM 3(10-11-2014).pdf 2014-11-10
58 2646-MUMNP-2010-FORM 3(10-12-2013).pdf 2013-12-10
58 2646-MUMNP-2010-FORM-27 [27-09-2024(online)].pdf 2024-09-27

ERegister / Renewals

3rd: 18 Dec 2017

From 04/06/2011 - To 04/06/2012

4th: 18 Dec 2017

From 04/06/2012 - To 04/06/2013

5th: 18 Dec 2017

From 04/06/2013 - To 04/06/2014

6th: 18 Dec 2017

From 04/06/2014 - To 04/06/2015

7th: 18 Dec 2017

From 04/06/2015 - To 04/06/2016

8th: 18 Dec 2017

From 04/06/2016 - To 04/06/2017

9th: 18 Dec 2017

From 04/06/2017 - To 04/06/2018

10th: 18 Dec 2017

From 04/06/2018 - To 04/06/2019

11th: 17 May 2019

From 04/06/2019 - To 04/06/2020

12th: 29 May 2020

From 04/06/2020 - To 04/06/2021

13th: 03 Jun 2021

From 04/06/2021 - To 04/06/2022

14th: 02 Jun 2022

From 04/06/2022 - To 04/06/2023

15th: 02 Jun 2023

From 04/06/2023 - To 04/06/2024

16th: 15 May 2024

From 04/06/2024 - To 04/06/2025

17th: 20 May 2025

From 04/06/2025 - To 04/06/2026